2,4-thiazolidinedione has been researched along with HIV-Associated Lipodystrophy Syndrome in 1 studies
thiazolidine-2,4-dione: structure in first source
1,3-thiazolidine-2,4-dione : A thiazolidenedione carrying oxo substituents at positions 2 and 4.
HIV-Associated Lipodystrophy Syndrome: Defective metabolism leading to fat maldistribution in patients infected with HIV. The etiology appears to be multifactorial and probably involves some combination of infection-induced alterations in metabolism, direct effects of antiretroviral therapy, and patient-related factors.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Vigouroux, C | 1 |
1 review available for 2,4-thiazolidinedione and HIV-Associated Lipodystrophy Syndrome
| Article | Year |
|---|---|
[Lipodystrophies: what treatment?].
Topics: Antiviral Agents; Diabetes Complications; Diabetes Mellitus; Diet; Exercise; HIV-Associated Lipodyst | 2003 |